LLY - Eli Lilly and Company
NYSE
->
Healthcare
->
Drug Manufacturers—General
Indianapolis,
United States
Type: Equity
LLY price evolution
LLY
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2818.6 | $2380.8 | $2694.5 | $3545.9 |
| Short term investments | $109.1 | $113.1 | $134.6 | $123.4 |
| Net receivables | $11336.2 | $10363.8 | $9171.4 | $9022.1 |
| Inventory | $5772.8 | $4901.4 | $4798.7 | $4544.8 |
| Total current assets | $25727 | $23007 | $21331.6 | $20811.4 |
| Long term investments | $3052.2 | $2691.7 | $2745.1 | $2750.4 |
| Property, plant & equipment | $12913.6 | $11863.2 | $11277.4 | $10546.2 |
| Goodwill & intangible assets | $11846.3 | $10866.9 | $10982.4 | $11160.2 |
| Total noncurrent assets | $38279.3 | $34908.5 | $33482.4 | $32351.6 |
| Total investments | $3161.3 | $2804.8 | $2879.7 | $2873.8 |
| Total assets | $64006.3 | $57915.5 | $54814 | $53163 |
| Current liabilities | ||||
| Accounts payable | $2598.8 | $2435.1 | $2474.2 | $2015.9 |
| Deferred revenue | ||||
| Short long term debt | $6904.5 | $2244.7 | $661.6 | $3.1 |
| Total current liabilities | $27293.2 | $21998.2 | $18915 | $16010 |
| Long term debt | $18320.8 | $17923.6 | $18158.4 | $18880.5 |
| Total noncurrent liabilities | $25849.4 | $24609.9 | $24749.7 | $25858.1 |
| Total debt | $25225.3 | $20168.3 | $18820 | $18883.6 |
| Total liabilities | $53142.6 | $46608.1 | $43664.7 | $41868.1 |
| Shareholders' equity | ||||
| Retained earnings | $10312.3 | $10309.9 | $10368.5 | $10639.3 |
| Other shareholder equity | -$4327 | -$3784.9 | -$3788.7 | -$3777.3 |
| Total shareholder equity | $10771.9 | $11220.4 | $11063.8 | $11190.4 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2818.6 | $2067 | $3818.5 | $3657.1 |
| Short term investments | $109.1 | $144.8 | $90.1 | $24.2 |
| Net receivables | $11336.2 | $8558.9 | $8127.2 | $6929 |
| Inventory | $5772.8 | $4309.7 | $3886 | $3980.3 |
| Total current assets | $25727 | $18034.5 | $18452.4 | $17462.1 |
| Long term investments | $3052.2 | $2901.8 | $3212.6 | $2966.8 |
| Property, plant & equipment | $12913.6 | $10144 | $8985.1 | $8681.9 |
| Goodwill & intangible assets | $11846.3 | $11279.6 | $11583.9 | $11216.5 |
| Total noncurrent assets | $38279.3 | $31455.3 | $30353.6 | $29171 |
| Total investments | $3161.3 | $3046.6 | $3302.7 | $2991 |
| Total assets | $64006.3 | $49489.8 | $48806 | $46633.1 |
| Current liabilities | ||||
| Accounts payable | $2598.8 | $1930.6 | $1670.6 | $1606.7 |
| Deferred revenue | ||||
| Short long term debt | $6904.5 | $1501.1 | $1538.3 | $8.7 |
| Total current liabilities | $27293.2 | $17138.2 | $15052.7 | $12481.6 |
| Long term debt | $18320.8 | $14737.5 | $15346.4 | $16586.6 |
| Total noncurrent liabilities | $25849.4 | $21576.2 | $24598.5 | $28326.3 |
| Total debt | $25225.3 | $16238.6 | $16884.7 | $16595.3 |
| Total liabilities | $53142.6 | $38840 | $39651.2 | $40807.9 |
| Shareholders' equity | ||||
| Retained earnings | $10312.3 | $10042.6 | $8958.5 | $7830.2 |
| Other shareholder equity | -$4327 | -$6820.7 | -$4343.1 | -$6496.4 |
| Total shareholder equity | $10771.9 | $10649.8 | $8979.2 | $5641.6 |
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9353.4 | $9498.6 | $8312.1 | $6960 |
| Cost of revenue | $1860.1 | $1807.4 | $1626.7 | |
| Gross Profit | $7565.4 | $7638.5 | $6504.7 | $5333.3 |
| Operating activities | ||||
| Research & development | $2409.1 | $2356.5 | $1985.1 | |
| Selling, general & administrative | $1803.9 | $1925.4 | $1749.2 | |
| Total operating expenses | $4487.3 | $7211.3 | $4415.8 | $3803.6 |
| Operating income | $427.2 | $2088.9 | $1529.7 | |
| Income from continuing operations | ||||
| EBIT | $427.2 | $2088.9 | $1529.7 | |
| Income tax expense | $319.2 | $484.6 | $325.7 | $184.8 |
| Interest expense | -$93.7 | |||
| Net income | ||||
| Net income | $2189.6 | -$57.4 | $1763.2 | $1344.9 |
| Income (for common shares) | -$57.4 | $1763.2 | $1344.9 | |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $34124.1 | $28541.4 | $24539.8 | |
| Cost of revenue | $6629.8 | $5483.3 | ||
| Gross Profit | $27041.9 | $21911.6 | $19056.5 | |
| Operating activities | ||||
| Research & development | $7190.8 | $6085.7 | ||
| Selling, general & administrative | $6440.4 | $6121.2 | ||
| Total operating expenses | $16716.5 | $15105.2 | $11826.6 | |
| Operating income | $6806.4 | $7229.9 | ||
| Income from continuing operations | ||||
| EBIT | $6806.4 | $7229.9 | ||
| Income tax expense | $1314.2 | $561.6 | $1036.2 | |
| Interest expense | -$312.3 | |||
| Net income | ||||
| Net income | $5240.4 | $6244.8 | $6193.7 | |
| Income (for common shares) | $6244.8 | $6193.7 | ||
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $2189.7 | -$57.4 | $1763.2 | $1344.9 |
| Operating activities | ||||
| Depreciation | $387.7 | $411 | $366.3 | $362.3 |
| Business acquisitions & disposals | -$1044.3 | |||
| Stock-based compensation | $120.2 | $215.6 | $161.5 | $131.2 |
| Total cash flows from operations | -$311.9 | $2189.5 | $631.9 | $1730.6 |
| Investing activities | ||||
| Capital expenditures | -$1070.6 | -$970.3 | -$738.2 | -$668.5 |
| Investments | -$206.1 | -$17.4 | -$79.6 | $174.4 |
| Total cash flows from investing | -$2924.3 | -$3080.5 | -$459.1 | -$688.8 |
| Financing activities | ||||
| Dividends paid | -$1018.1 | -$1016.2 | -$1017.8 | -$1017.2 |
| Sale and purchase of stock | -$750 | |||
| Net borrowings | $4594.4 | $1595 | $2460.5 | |
| Total cash flows from financing | $3544.7 | $572 | -$1033.4 | $412.3 |
| Effect of exchange rate | $129.3 | $5.3 | $9.2 | $24.8 |
| Change in cash and equivalents | $437.8 | -$313.7 | -$851.4 | $1478.9 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $5240.4 | $6244.8 | $5581.7 | $6193.7 |
| Operating activities | ||||
| Depreciation | $1527.3 | $1522.5 | $1547.6 | $1323.9 |
| Business acquisitions & disposals | -$1044.3 | -$327.2 | -$747.4 | -$849.3 |
| Stock-based compensation | $628.5 | $371.1 | $342.8 | $308.1 |
| Total cash flows from operations | $4240.1 | $7084.4 | $7260.7 | $6499.6 |
| Investing activities | ||||
| Capital expenditures | -$3447.6 | -$1854.3 | -$1309.8 | -$1387.9 |
| Investments | -$128.7 | -$244 | -$166 | $516.7 |
| Total cash flows from investing | -$7152.7 | -$3261.6 | -$2762.3 | -$2258.9 |
| Financing activities | ||||
| Dividends paid | -$4069.3 | -$3535.8 | -$3086.8 | -$2687.1 |
| Sale and purchase of stock | -$750 | -$1500 | -$1250 | -$500 |
| Net borrowings | $8649.9 | -$62 | $501.4 | $291.6 |
| Total cash flows from financing | $3495.6 | -$5406.7 | -$4131.3 | -$3137.1 |
| Effect of exchange rate | $168.6 | -$167.6 | -$205.7 | $216 |
| Change in cash and equivalents | $751.6 | -$1751.5 | $161.4 | $1319.6 |
News
|
The Week in Pictures: April 5 - April 12
dpa international via Yahoo News
12 Apr 2024
|
|
GLP-1s benefit Parkinson’s: Barclays sees biopharma impact
Seeking Alpha
12 Apr 2024
|
|
Trillion-Dollar Trajectories: 3 Billion-Dollar Stocks With the Potential to Hit the Next Milestone
InvestorPlace
11 Apr 2024
|
|
Jim Cramer Stands By Nvidia And Eli Lilly Despite Market Dips, Says 'Terrific Time To Take Some...
Benzinga
9 Apr 2024
|
|
Eli Lilly eyes $2.5B plant to make obesity drugs (NYSE:LLY)
Seeking Alpha
9 Apr 2024
|
|
Diabetes drug may delay heart failure hospitalizations
Futurity
9 Apr 2024
|
|
11 Best Biotech ETFs To Buy
Insider Monkey via Yahoo Finance
9 Apr 2024
|
|
10 Best Weight Loss Drug Stocks to Buy Now
Insider Monkey via Yahoo Finance
7 Apr 2024
|
|
Top three US healthcare stocks to buy in April | Invezz Top three US healthcare stocks to buy in...
Invezz
4 Apr 2024
|
|
Billionaire Stanley Druckenmiller’s Top 12 Stock Picks
Insider Monkey via Yahoo Finance
27 Mar 2024
|
Fundamentals
| Market cap | $708.19B |
|---|---|
| Enterprise value | $730.60B |
| Shares outstanding | 949.38M |
| Revenue | $34.12B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $5.24B |
| Revenue Q/Q | 28.10% |
| Revenue Y/Y | 19.56% |
| P/E ratio | 135.14 |
|---|---|
| EV/Sales | 21.41 |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 20.75 |
| P/B ratio | 46.90 |
| Book/Share | 15.90 |
| Cash/Share | 2.97 |
| EPS | $5.52 |
|---|---|
| ROA | 9.12% |
| ROE | 47.37% |
| Debt/Equity | 4.93 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.94 |
| Quick ratio | 0.73 |